Market Cap 279.66B
Revenue (ttm) 51.72B
Net Income (ttm) 11.94B
EPS (ttm) N/A
PE Ratio 14.99
Forward PE 14.55
Profit Margin 23.09%
Debt to Equity Ratio 0.73
Volume 1,415,400
Avg Vol 1,363,124
Day's Range N/A - N/A
Shares Out 2.11B
Stochastic %K 91%
Beta 0.64
Analysts Sell
Price Target $120.28

Company Profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CD...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 324 11 11
Fax: 41 61 324 80 01
Address:
Lichtstrasse 35, Basel, Switzerland
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 5 at 3:16 AM
$SLS The ’secondary asset’ 009 is right now Worth 15-20x the current short manipulated $220M MCAP. $PFE Pfizers' Ibrance - palbociclib CDKinase Inhibitor $NVS Novartis' Kisqali -ribociclib CDKinase Inhibitor $LLY Eli Lilly's Verzenio -abemaciclib CDKinase Inhibitor SLS009 /Tambiciclib CDKInase Inhibitor Don’t Forget REGOR‘s CDKinase Asset was bought for a total of $4B in Ph 1/2. .
0 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 3:11 AM
$NVS: Unusual Options Activity Alerted CALL flow observed 300x contracts at Strike price of $135 Exp on 10/17/2025 with Premium of $33K and showing BULLISH Sentiment
0 · Reply
wwmeinc
wwmeinc Oct. 3 at 7:50 PM
$RNA ...ATH on $NVS today....over $257B M/C....lots of firepower, should they ever decide to be in the buying mood here....Avidity shareholders await ;) glta https://www.investing.com/equities/avidity-biosciences-inc
0 · Reply
highnihilism
highnihilism Oct. 3 at 5:17 PM
$MESO Mesoblast Trades: 155 | Total $: 424.9 K | 1.84 × 90-Day Avg $: 230.4 K | Call $: 419.8 K | Put $: 5.2 K | Single-Leg: 56% | Multi-Leg: 44% $NVS Novartis Trades: 185 | Total $: 518.9 K | 1.38 × 90-Day Avg $: 376.7 K | Call $: 417.4 K | Put $: 101.6 K | Single-Leg: 96% | Multi-Leg: 4% $BUD Anheuser-Busch Inbev Trades: 192 | Total $: 498.8 K | 0.47 × 90-Day Avg $: 1.06 M | Call $: 416.8 K | Put $: 82.1 K | Single-Leg: 97% | Multi-Leg: 3% $HCA HCA Healthcare Trades: 247 | Total $: 526.9 K | 0.30 × 90-Day Avg $: 1.74 M | Call $: 415.7 K | Put $: 111.2 K | Single-Leg: 34% | Multi-Leg: 66%
0 · Reply
lexlut
lexlut Oct. 3 at 2:45 PM
$NVS Buy CMPX
0 · Reply
RunnerSignals
RunnerSignals Oct. 3 at 12:03 PM
All-Time High Watch 🚀 $AZN $NG $NVS $TLRY $VRT all touched fresh highs, showing strong momentum. Some near resistance, but trends still look powerful https://stocksrunner.com/news/2025-10-03-daily-market-pulse-advanced-technical-analysis-and-trading-signals
0 · Reply
RunnerSignals
RunnerSignals Oct. 2 at 7:57 PM
All-Time High Watch $AZN $NG $NVS breaking to new highs while $PLTR patterns improve and $NEXT sits oversold https://stocksrunner.com/news/2025-10-02-daily-market-pulse-key-technical-trends-you-need-now
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 7:31 AM
$NVS: Unusual Options Activity Alerted PUT flow observed 13x contracts at Strike price of $145 Exp on 04/17/2026 with Premium of $29K and showing BULLISH Sentiment
0 · Reply
Quantumup
Quantumup Oct. 1 at 2:41 PM
Oppenheimer reiterated $FULC at an Outperform rating and a $15 price target: $XBI $AGIO $NVS $VRTX Oppenheimer said: We've been getting questions on how updated pociredir data later this year will impact FULC shares. For us, the readout is more "icing on the cake," rather than major binary because we already thought pociredir looked like a drug at the lower 12 mg dose. Absent any idiosyncratic toxicity or material weakening of efficacy, shares should continue to grind higher. However, given Fulcrum's recent run (shares are up 80% YTD vs. the XBI ahead 9%), it's fair to assume that the buyside's internal bar may be higher than our own. Based on our field work, that bar appears to be a 10% or higher HbF improvement. We believe that's achievable based on prior healthy volunteer data.
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 1 at 1:32 PM
$CDXS $NVS That being said the COO at Novartis, Steffen Lang, sits on the BoD at Bachem....interesting coincidence! https://www.novartis.com/about/executive-committee/steffen-lang
2 · Reply
Latest News on NVS
US FDA approves Novartis' drug for skin disease

Sep 30, 2025, 4:22 PM EDT - 4 days ago

US FDA approves Novartis' drug for skin disease


Novartis, Monte Rosa strike $5.7 billion drug development deal

Sep 15, 2025, 7:15 AM EDT - 19 days ago

Novartis, Monte Rosa strike $5.7 billion drug development deal


Novartis: Pipeline Progress And Buyback Drive Upside

Sep 3, 2025, 4:16 AM EDT - 4 weeks ago

Novartis: Pipeline Progress And Buyback Drive Upside


Swiss government to meet pharma firms to discuss US tariffs

Aug 11, 2025, 10:40 AM EDT - 7 weeks ago

Swiss government to meet pharma firms to discuss US tariffs


Novartis AG (NVS) Q2 2025 Earnings Call Transcript

Jul 21, 2025, 2:50 AM EDT - 2 months ago

Novartis AG (NVS) Q2 2025 Earnings Call Transcript


Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 5 at 3:16 AM
$SLS The ’secondary asset’ 009 is right now Worth 15-20x the current short manipulated $220M MCAP. $PFE Pfizers' Ibrance - palbociclib CDKinase Inhibitor $NVS Novartis' Kisqali -ribociclib CDKinase Inhibitor $LLY Eli Lilly's Verzenio -abemaciclib CDKinase Inhibitor SLS009 /Tambiciclib CDKInase Inhibitor Don’t Forget REGOR‘s CDKinase Asset was bought for a total of $4B in Ph 1/2. .
0 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 3:11 AM
$NVS: Unusual Options Activity Alerted CALL flow observed 300x contracts at Strike price of $135 Exp on 10/17/2025 with Premium of $33K and showing BULLISH Sentiment
0 · Reply
wwmeinc
wwmeinc Oct. 3 at 7:50 PM
$RNA ...ATH on $NVS today....over $257B M/C....lots of firepower, should they ever decide to be in the buying mood here....Avidity shareholders await ;) glta https://www.investing.com/equities/avidity-biosciences-inc
0 · Reply
highnihilism
highnihilism Oct. 3 at 5:17 PM
$MESO Mesoblast Trades: 155 | Total $: 424.9 K | 1.84 × 90-Day Avg $: 230.4 K | Call $: 419.8 K | Put $: 5.2 K | Single-Leg: 56% | Multi-Leg: 44% $NVS Novartis Trades: 185 | Total $: 518.9 K | 1.38 × 90-Day Avg $: 376.7 K | Call $: 417.4 K | Put $: 101.6 K | Single-Leg: 96% | Multi-Leg: 4% $BUD Anheuser-Busch Inbev Trades: 192 | Total $: 498.8 K | 0.47 × 90-Day Avg $: 1.06 M | Call $: 416.8 K | Put $: 82.1 K | Single-Leg: 97% | Multi-Leg: 3% $HCA HCA Healthcare Trades: 247 | Total $: 526.9 K | 0.30 × 90-Day Avg $: 1.74 M | Call $: 415.7 K | Put $: 111.2 K | Single-Leg: 34% | Multi-Leg: 66%
0 · Reply
lexlut
lexlut Oct. 3 at 2:45 PM
$NVS Buy CMPX
0 · Reply
RunnerSignals
RunnerSignals Oct. 3 at 12:03 PM
All-Time High Watch 🚀 $AZN $NG $NVS $TLRY $VRT all touched fresh highs, showing strong momentum. Some near resistance, but trends still look powerful https://stocksrunner.com/news/2025-10-03-daily-market-pulse-advanced-technical-analysis-and-trading-signals
0 · Reply
RunnerSignals
RunnerSignals Oct. 2 at 7:57 PM
All-Time High Watch $AZN $NG $NVS breaking to new highs while $PLTR patterns improve and $NEXT sits oversold https://stocksrunner.com/news/2025-10-02-daily-market-pulse-key-technical-trends-you-need-now
0 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 7:31 AM
$NVS: Unusual Options Activity Alerted PUT flow observed 13x contracts at Strike price of $145 Exp on 04/17/2026 with Premium of $29K and showing BULLISH Sentiment
0 · Reply
Quantumup
Quantumup Oct. 1 at 2:41 PM
Oppenheimer reiterated $FULC at an Outperform rating and a $15 price target: $XBI $AGIO $NVS $VRTX Oppenheimer said: We've been getting questions on how updated pociredir data later this year will impact FULC shares. For us, the readout is more "icing on the cake," rather than major binary because we already thought pociredir looked like a drug at the lower 12 mg dose. Absent any idiosyncratic toxicity or material weakening of efficacy, shares should continue to grind higher. However, given Fulcrum's recent run (shares are up 80% YTD vs. the XBI ahead 9%), it's fair to assume that the buyside's internal bar may be higher than our own. Based on our field work, that bar appears to be a 10% or higher HbF improvement. We believe that's achievable based on prior healthy volunteer data.
0 · Reply
Fingerlickengood
Fingerlickengood Oct. 1 at 1:32 PM
$CDXS $NVS That being said the COO at Novartis, Steffen Lang, sits on the BoD at Bachem....interesting coincidence! https://www.novartis.com/about/executive-committee/steffen-lang
2 · Reply
Fingerlickengood
Fingerlickengood Sep. 30 at 4:27 PM
$NVS You gotta wonder, where the specific enzyme was designed/synthesized that $CDXS and $BCHMF are now using in he ECO Lab to produce Inclisiran. This all seems too coincidental. https://www.codexis.com/investors/news-events/press-releases/detail/296/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 30 at 4:20 PM
$CDXS $NVS Considering the recent efforts to source all pharmaceutical drugs from manufacturers in the US to avoid heavy tariffs, and the announcement last November that Codexis and Bachem were able to efficiently manufacture Inclisiran (aka Leqvio) using an enzymatic process. I think we are well overdue for something BIG pertaining specifically to this in the near future! We will see! https://www.msn.com/en-za/news/other/jab-for-high-cholesterol-could-transform-heart-care/ar-AA1LxVYc?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 30 at 3:15 PM
$CDXS $NVS https://www.pharmacytimes.com/view/inclisiran-shows-good-toleration-and-substantial-ldl-c-reductions-in-real-world-practice
0 · Reply
highnihilism
highnihilism Sep. 30 at 8:53 AM
$CFG Citizens Financial: 182 trades, $324K vs $360K avg (0.90x). $122K calls / $201K puts. $NVS Novartis: 196 trades, $410K vs $367K avg (1.12x). $122K calls / $288K puts. $CLBT Cellebrite: 117 trades, $169K vs $70K avg (2.41x !). $122K calls / $47K puts. $FN Fabrinet: 35 trades, $148K vs $582K avg (0.25x). $122K calls / $26K puts.
0 · Reply
TechTraderGrok
TechTraderGrok Sep. 29 at 8:06 PM
Bought $NVS at $124.03. From Grok: "Entering long on bounce from rising support at ~122.73 in clear uptrend with EMA above SMA and price above both, targeting resistance near 130, despite recent exit but at better price after pullback with improved risk/reward." https://www.techtrader.ai/grokwall/?post=15014&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
DonCorleone77
DonCorleone77 Sep. 26 at 2:50 AM
$AZN $GSK $NVS $RHHBY $BMY Trump to impose 100% tariff on drugs unless manufacturer building U.S. plant In a post on Truth Social, President Trump stated the following: "Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. "IS BUILDING" will be defined as, "breaking ground" and/or "under construction." There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started. Thank you for your attention to this matter!"
2 · Reply
lextrading
lextrading Sep. 26 at 12:09 AM
$NVO $PFE $NVS 100% tariff branded drugs. Yesterday, I shared in my Discord that a $6.3M put order came for $XLV . Someone always knows!!!
0 · Reply
SweepCastApp
SweepCastApp Sep. 25 at 10:55 PM
$NVS: TRADE CALL orders came through 10 @ 31.77, Strike 100.0, Exp 1/21/2028, Premium $31,770, Sentiment BEARISH
0 · Reply
OptionRunners
OptionRunners Sep. 25 at 3:34 PM
$NVS Buyer of the October 17th $125 puts (ITM) 1,200 times for $3.10-$3.30
0 · Reply
lexlut
lexlut Sep. 23 at 1:37 PM
$NVS CMPX
0 · Reply
lexlut
lexlut Sep. 22 at 7:41 PM
$NVS CMPX new acquisition
0 · Reply
biotech
biotech Sep. 22 at 1:50 PM
$SGMO Trump #Austism: thats the $SGMO $NVS work that Novartis gave back for not having the probber #delivery method... only 1 year later $SGMO solved delivery via #STAC_BBB this work should be partner ready and could come into clinic fast
1 · Reply